Patents by Inventor Grant A. Krafft

Grant A. Krafft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080014596
    Abstract: Disclosed herein are methods for the quantification of ADDL binding to neuronal cells, including, but not limited to, primary cultures of hippocampal neurons. The method identifies and selects neurons based on any means capable of distinguishing neuronal cells, including, but not limited to, MAP2 immunoreactivity, which ensures that glial cells are excluded from an ADDL binding analysis; antibodies selective for neuronal cell surface receptors and/or other surface markers; reagents specific for neuronal signalling markers present intracellularly; and the like. Furthermore, ADDL binding occurs in a sub-population of 16 DIV neurons and is heterogeneous in intensity among individual cells. Also, ADDL binding can be further specified and quantified by using additional markers. Additionally, the presence or absence of ADDL binding is used to identify, characterize, analyze, assess, and/or evaluate agents (e.g.
    Type: Application
    Filed: November 16, 2006
    Publication date: January 17, 2008
    Inventors: Jasna Jerecic, Grant A. Krafft
  • Publication number: 20040138296
    Abstract: The present invention provides compositions and methods for the treatment or prevention of Alzheimer's disease. More particularly, the invention provides a combination therapy for the treatment or prevention of Alzheimer's disease, wherein the therapy comprises administering to a subject an amyloid beta vaccine in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: July 25, 2003
    Publication date: July 15, 2004
    Applicant: Pharmacia Corporation
    Inventors: David W. Robertson, Grant A. Krafft
  • Publication number: 20030068316
    Abstract: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid &bgr; protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.
    Type: Application
    Filed: June 11, 2002
    Publication date: April 10, 2003
    Inventors: William L. Klein, Grant A. Krafft, Mary P. Lambert, Kirsten L. Viola, Brett A. Chromy, Yue Song Gong, Lei Chang, Todd E. Morgan, Irina Rozofsky, Caleb E. Finch
  • Patent number: 6218506
    Abstract: The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid &bgr; peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: April 17, 2001
    Assignees: Northwestern University, University of Southern California
    Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Mary P. Lambert, Caleb E. Finch, Todd Morgan, Pat Wals, Irina Rozovsky, Ann Barlow
  • Patent number: 5843634
    Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Elaine M Brate, Catherine A. Brennan, Dominique P. Bridon, Keeve D. Jaffe, Grant A. Krafft, Wlodzimierz Mandecki, Steven C. March, John C. Russell, Vincent T. Yue